| Summary: | Multiple myeloma (MM) is characterized by extensive immunoglobulin production leading to an excessive load on protein homeostasis in tumor cells. Aminopeptidases contribute to proteolysis by catalyzing the hydrolysis of amino acids from proteins or peptides and function downstream of the ubiquitin–proteasome pathway. Notably, aminopeptidases can be utilized in the delivery of antibody and peptide-conjugated drugs, such as melflufen, currently in clinical trials. We analyzed the expression of 39 aminopeptidase genes in MM samples from 122 patients treated at Finnish cancer centers and 892 patients from the CoMMpass database. Based on ranked abundance, <i>LAP3</i>, <i>ERAP2</i>, <i>METAP2</i>, <i>TTP2</i>, and <i>DPP7</i> were highly expressed in MM. <i>ERAP2</i>, <i>XPNPEP1</i>, <i>DPP3</i>, <i>RNPEP</i>, and <i>CTSV</i> were differentially expressed between relapsed/refractory and newly diagnosed MM samples (<i>p</i> < 0.05). Sensitivity to melflufen was detected ex vivo in 11/15 MM patient samples, and high sensitivity was observed, especially in relapsed/refractory samples. Survival analysis revealed that high expression of <i>XPNPEP1</i>, <i>RNPEP</i>, <i>DPP3</i>, and <i>BLMH</i> (<i>p</i> < 0.05) was associated with shorter overall survival. Hydrolysis analysis demonstrated that melflufen is a substrate for aminopeptidases LAP3, LTA4H, RNPEP, and ANPEP. The sensitivity of MM cell lines to melflufen was reduced by aminopeptidase inhibitors. These results indicate critical roles of aminopeptidases in disease progression and the activity of melflufen in MM.
|
|---|